Clinical Outcomes of Covid-19 in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study

Derikx, Lauranne A A P; Lantinga, Marten A; de Jong, Dirk J; van Dop, Willemijn A; Creemers, Rob H; Römkens, Tessa E H; Jansen, Jeroen M; Mahmmod, Nofel; West, Rachel L; Tan, Adriaan C I T L; Bodelier, Alexander G L; Gorter, Moniek H P; Boekema, Paul J; Halet, Eric R C; Horjus, Carmen S; van Dijk, Maarten A; Hirdes, Meike M C; Epping Stippel, Ludger S M; Jharap, Bindia; Lutgens, Maurice W M D; Russel, Maurice G; Gilissen, Lennard P L; Nauta, Sjoukje; van Bodegraven, Adriaan A; Hoentjen, Frank

BACKGROUND AND AIMS: The COVID-19 risk and disease course in inflammatory bowel disease (IBD) patients remains uncertain. Therefore, we aimed to assess the clinical presentation, disease course and outcomes of COVID-19 in IBD patients. Second, we determined COVID-19 incidences in IBD patients and compared this with the general population. METHODS: We conducted a multicenter, nationwide IBD cohort study in the Netherlands and identified patients with COVID-19. First, we assessed the COVID-19 disease course and outcomes. Second, we compared COVID-19 incidences between our IBD study cohort and the general Dutch population. RESULTS: We established an IBD cohort of 34,763 patients. COVID-19 was diagnosed in 100/34,763 patients (0.29%). 20/100 patients (20%) had severe COVID-19 defined as admission to the intensive care unit, mechanical ventilation, and/or death. Hospitalization occurred in 59/100 (59.0%) patients and 13/100 (13.0%) died. All patients who deceased had comorbidities and all but one were > 65 years. In line, we identified > 1 comorbidity as an independent risk factor for hospitalization (OR 4.20, 95% CI 1.58-11.17, p = 0.004). Incidences of COVID-19 between the IBD study cohort and the general population were comparable (287.6 (95% CI 236.6-349.7) versus 333.0 (95% CI 329.3-336.7) per 100,000 patients, respectively; p = 0.15). CONCLUSIONS: Of 100 cases with IBD and COVID-19, 20% developed severe COVID-19, 59% was hospitalized and 13% died. A comparable COVID-19 risk was found between the IBD cohort (100/34,763 = 0.29%) and the general Dutch population. The presence of > 1 comorbidities was an independent risk factor for hospitalization due to COVID-19.